Status:
UNKNOWN
Assessing Effectiveness of Community Acquired Pneumonia Treatment by Continuous Pneumonia Severity Score
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions:
Community-acquired Pneumonia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Community acquired pneumonia (CAP) is a common respiratory infection and is the main cause of ICU admission and death in adults. Because of most patients were treated empirically against suspected cau...
Detailed Description
The applicant has established a CAP patients database and found a new effective pneumonia severity score: Expand-CURB. According to the retrospective study results, applicant found the changes of pneu...
Eligibility Criteria
Inclusion
- community acquired pneumonia(by CTS or IDSA/ATS guidelines)
- severe community acquired pneumonia(PSI scores \>= 90 or Expand-CURB scores \>= 4);
Exclusion
- HIV patients
- Other immunodeficiency disorders (neutropenia, hematologic and solid tumors undergoing chemoradiotherapy, organ transplantation, and long-term treatment with glucocorticoid and cytokine antagonists).
Key Trial Info
Start Date :
July 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT04135183
Start Date
July 1 2020
End Date
December 31 2022
Last Update
October 22 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SAHZhejiangU
Hangzhou, Zhejiang, China, 310000